Clinical Trial Update: A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating YM060 for efficacy and safety in female patients with diarrhea-predominant irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• YM060

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Diarrhea-predominant Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED